Cross-Sector entity
FiscalAI is most often covered alongside Weiss Ratings, which appears in 12 of these 15 stories. Across a 22-day span, the pace is roughly 4.8 stories per week. The busiest single day carried 6. Coverage clusters in earnings, which accounts for 9 of those 15, with the remainder spread across 5 other categories.
15 verified stories tracked
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FiscalAI is most often covered alongside Weiss Ratings, which appears in 12 of these 15 stories. Across a 22-day span, the pace is roughly 4.8 stories per week. The busiest single day carried 6. Coverage clusters in earnings, which accounts for 9 of those 15, with the remainder spread across 5 other categories. FiscalAI appears in 15 tracked Cross-Sector stories published from August 1, 2026 through August 22, 2026. Negative sentiment appears in 0% of the tracked stories. Each carries 2.1 original sources on average.
Computed from the 15 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FiscalAI. Shared-story counts are live from our verified record — not editorial picks.
Dividend payment
The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
Ex-dividend date
Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
EchoStar announces quarterly earnings
EchoStar reports EPS of $24.12, exceeding the consensus estimate of -$0.02 by $24.14. Revenue of $3.58 billion falls slightly short of the $3.59 billion estimate.
Baird price target and stock rebound
Robert W. Baird set a $66.00 price target; the stock traded up to $57.60, rising $1.79.
Q2 2026 earnings release
Middlesex Water reported Q2 EPS of $0.79 on revenue of $56.36 million; shares closed at $55.81, down $1.44.
Maxim Group downgrades to Hold
Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Weiss Ratings downgrade
Weiss Ratings cut Middlesex Water from 'hold (c)' to 'hold (c-)'.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
New Street Research target
New Street Research set a $64.00 price target on Middlesex Water.
Weiss Ratings reiterates Sell (E+)
Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.
CEO Hamid Akhavan sold 52,586 shares
The sale was executed under a pre-arranged Rule 10b5-1 trading plan at $121.00 per share, totaling $6,362,906, reducing his ownership by 5.73%.
Wall Street Zen rating action
Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
Wall Street Zen downgrades MBRX
Cut its rating from 'sell' to 'strong sell' in a research note
Wall Street Zen upgrade
Wall Street Zen upgraded Middlesex Water from 'sell' to 'hold'.
Jane Street Group discloses new MBRX position
Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Silexion beat consensus by $16.03 with a ($5.17) EPS, yet shares fell to $0.42. With volume at 2x average, a 52-week high of $80, and Hold consensus, the microcap has shed nearly all value.
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Source: themarketsdaily.com · dailypolitical.com
Seneca Foods posted a top-line beat of $405.17M, 24% above estimates, despite a $0.07 EPS miss, driving a 7.4% stock surge and Strong Buy ratings. Talkspace, meanwhile, missed on both EPS and revenue, but its stock held steady as institutional investors continued accumulating shares.
Source: themarketsdaily.com · dailypolitical.com
Micro-cap dry bulk shipper United Maritime posted a $0.15 EPS, beating estimates by $0.12, on revenue of $9.99M. The beat, paired with a high dividend yield, may signal improving charter rates and tightening shipping capacity, offering critical insights for supply chain planners monitoring freight cost trends.
Source: dailypolitical.com · themarketsdaily.com
Ellington Financial, Genpact, and BCE all reported better-than-expected earnings this week. Reactions diverged: EFC rallied, while Genpact and BCE slipped. Income investors are drawn to yields as high as 11.5%, but analyst downgrades and cautious guidance warrant scrutiny.
Source: MarketBeat · themarketsdaily.com
EchoStar reported a massive $24.12 EPS versus expected -$0.02, topping estimates by $24.14. Revenue of $3.58B missed the mark slightly and fell 4% year-over-year. The divergence raises questions about earnings quality, while an insider stock sale by the CEO adds caution.
Source: tickerreport.com · dailypolitical.com
Middlesex Water's Q2 EPS of $0.79 surged past estimates, reinforcing its reputation as a stable income play. With a 2.5% yield and 60% payout ratio, the utility delivered strong net margins of 22.07%. However, mixed analyst ratings and a beta of 0.78 suggest cautious optimism.
Source: MarketBeat · dailypolitical.com
